

64

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication: **28.08.2002** Bulletin 2002/35 (51) Int Cl.7: **A61K 47/48, A61P 35/00**

(21) Application number: **01104640.6**

(22) Date of filing: **23.02.2001**

<p>(84) Designated Contracting States: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated Extension States: AL LT LV MK RO SI</p> <p>(71) Applicant: F. HOFFMANN-LA ROCHE AG 4070 Basel (CH)</p>	<p>(72) Inventor: The designation of the inventor has not yet been filed</p> <p>(74) Representative: Schreiner, Siegfried, Dr. et al Roche Diagnostics GmbH, Patent Department (TR-E), P.O. Box 1152 82372 Penzberg (DE)</p>
--	--

(54) **PEG-conjugates of HGF-NK4**

(57) A conjugate comprising an N-terminal fragment of hepatocyte growth factor (HGF/SF) consisting of the hairpin domain and the four kringle regions of the α -chain and one to three polyethylene glycol group(s), said polyethylene glycol group(s) having an overall mo-

lecular weight of from about 10 to 40 kDa, has improved properties and is a useful therapeutic agent for tumor treatment.

Description

[0001] This invention relates to conjugates of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) with polyethylene glycol (PEG), pharmaceutical compositions thereof, methods for the production and methods for use.

Background of the Invention

[0002] Hepatocyte growth factor (HGF/SF) is a polypeptide identified and purified by Nakamura, T., et al., *Biochem. Biophys. Res. Commun.* 22 (1984) 1450-1459. It was further found that hepatocyte growth factor is identical to scatter factor (SF), Weidner, K.M., et al., *Proc. Natl. Acad. Sci. USA* 88 (1991) 7001-7005. HGF is a glycoprotein involved in the development of a number of cellular phenotypes including proliferation, mitogenesis, formation of branching tubules and, in the case of tumor cells, invasion and metastasis. For a status review, see Stuart, K.A., et al., *International Journal of Experimental Pathology* 81 (2000) 17-30.

[0003] Both rat HGF and human HGF have been sequenced and cloned (Miyazawa, K. et al., *Biochem. Biophys. Res. Comm.* 163 (1989) 967-973; Nakamura, T., et al., *Nature* 342 (1989) 440-443; Seki, T., et al., *Biochem. and Biophys. Res. Comm.* 172 (1990) 321-327; Tashiro, K., et al., *Proc. Natl. Acad. Sci. USA* 87 (1990) 3200-3204; Okajima, A., et al., *Eur. J. Biochem.* 193 (1990) 375-381).

[0004] U.S. Patent No. 5,977,310 describes PEG-modified HGF. Such PEG-modified HGF has a prolonged clearance in vivo and has the same physiological activity as HGF. However, according to U.S. Patent No. 5,977,310, it is only possible to prolong the half life of HGF from 59.2 minutes to 76.7 minutes or 95.6 minutes, respectively (see Example 5 of U.S. Patent No. 5,977,310). It is further suggested in this patent that the molar amount of the PEG reagent may be selected from the range of from 5 to 100 times of the molar weight of HGF. In the case of modifying an amino group of lysine or the N-terminus of protein, a preferred molar range of the PEG reagent is of from 10 to 25 times of the molar weight of HGF. The molecular weight of the attached PEG chain was about 10 kDa.

[0005] It was further found that an HGF/SF fragment, termed NK4, consisting of the N-terminal hairpin domain and the four kringle domains of HGF/SF has pharmacological properties that are completely different from those of HGF/SF, and is an antagonist to the influence of HGF/SF on the motility and the invasion of colon cancer cells, and is, in addition, an angiogenesis inhibitor that suppresses tumor growth and metastasis (Parr, C., et al., *Int. J. Cancer* 85 (2000) 563-570; Kuba, K., et al., *Cancer Res.* 60 (2000) 6737-6743; Date, K., et al., *FEBS Letters* 420 (1997) 1-6; Date, K., et al., *Oncogene* 17 (1999) 3045-3054).

[0006] According to the state of the art, NK4 is, however, not a substance that appears suitable for easy therapeutic use in humans. As emerges from Kuba, K., et al., *Cancer Res.* 60 (2000) 6737-6743, in animal experiments, for detecting an effect of NK4 on lung metastases, NK4 had to be infused continuously over a period of two weeks.

[0007] It is known that the attachment of polymers to certain polypeptides may increase the serum half life of such polypeptides. This was found, for example, for pegylated Interleukin-6 (EP 0 442 724) or Interleukin-2 (WO 90/07938) and erythropoietin (WO 01/02017). However, the attachment of polyethylene glycol and other polymers did not necessarily lead to prolongation of their serum half lives. It is known, for example, that the conjugation of different polyethylene glycols to Interleukin-8, G-CSF and other interleukins results in the production of molecules with impaired properties (Gaertner, H.F., and Offord, R.E., *Bioconjugate Chem.* 7 (1996) 38-44; Mehvar, R., *J. Pharm. Pharm. Sci.* 3 (1) (2000) 125-136). Thus, the outcome of a pegylation of a polypeptide is highly unpredictable.

[0008] It was an object of the present invention to find an improved pharmaceutical composition for NK4, which composition can be administered as only a few, bolus applications per week and which is capable of suppressing tumor growth, angiogenesis and metastasis.

Summary of the Invention

[0009] The present invention provides NK4 conjugates consisting of NK4 being covalently linked to from one to three polyethylene glycol (PEG) groups (pegylated NK4).

[0010] It has been found, surprisingly, that pegylated, preferably monopegylated, NK4 according to the invention has superior properties in regard to the therapeutic applicability.

[0011] The invention further comprises a method for the production of pegylated NK4.

[0012] The invention further comprises pharmaceutical compositions containing pegylated NK4.

[0013] The invention further comprises methods for the production of pharmaceutical compositions containing pegylated NK4.

[0014] The invention further comprises methods for the treatment of human cancer (e.g. breast, lung, prostate or colon cancer) characterized in that a pharmaceutically effective amount of pegylated NK4 is administered in one to seven bolus applications per week to the patient in need thereof.

Detailed Description of the Invention

[0015] Human HGF is a disulfide-linked heterodimer, which can be cleaved in an α -subunit of 463 amino acids and a β -subunit of 234 amino acids, by cleavage between amino acids R494 and V495. The N-terminus of the α -chain is preceded by 31 amino acids started with a methionine group. This segment includes a signal sequence of 31 amino acids. The α -chain starts at amino acid 32 and contains four kringle domains. The so-called "hairpin domain" consists of amino acids 70-96. The kringle 1 domain consists of amino acids 128-206. The kringle 2 domain consists of amino acids 211-288, the kringle 3 domain consists of amino acids 305-383, and the kringle 4 domain consists of amino acids 391-469 of the α -chain, approximately. There exist variations of these sequences, essentially not affecting the biological properties of NK4 (especially not affecting its activities antagonistic to HGF and its antiangiogenic activities), which variations are described, for example, in WO 93/23541. Also the length of NK4 can vary within a few amino acids as long as its biological properties are not affected.

[0016] NK4 is composed of the N-terminal 447 amino acids of the HGF/SF α -chain, which includes the above-mentioned four kringle domains. It can be produced recombinantly, either by the production of recombinant human HGF/SF and digestion with elastase (Date, K., FEBS Letters 420 (1997) 1-6) or by recombinant expression of an NK4 encoding nucleic acid in appropriate host cells, as described below. NK4 glycoprotein has a molecular weight of about 57 kDa (52 kDa for the polypeptide part alone) and has the in vivo biological activity of causing inhibition of tumor growth, angiogenesis and/or metastasis.

[0017] The invention provides pegylated forms of NK4 with improved properties. Such pegylated NK4 contains one to three PEG groups attached thereto, whereby the overall molecular weight of all PEG groups in the conjugate is 10 to 40 kDa, preferably 20 to 40 kDa. This implies that the pegylated forms of NK4 according to the invention comprise, for example,

- monopegylated NK4, the PEG group having a molecular weight of 10, 20, 30 or 40 kDa;
- dipegylated NK4, the PEG groups having a molecular weight of 10 or 20 kDa each;
- tripegylated NK4, the PEG groups having a molecular weight of 10 kDa each, or mixtures thereof.

[0018] "Pegylated NK4" as used herein therefore means that NK4 has attached covalently one, two or three polyethylene glycol groups. The groups can be attached at different sites of the NK4 molecule, preferably, however, at the most reactive sites, e.g., the lysine side chains. Due to the synthesis method used, "pegylated NK4" can consist of a mixture of mono-, di- and/or tripegylated NK4, whereby the sites of pegylations can be different in different molecules or can be substantially homogeneous in regard to the amount of polyethylene glycol side chains per molecule and/or the site of pegylation in the molecule. Isolation and purification of such homogeneous preparations of pegylated NK4 can be performed by usual purification methods, preferably size exclusion chromatography.

[0019] "Substantially homogeneous" as used herein means that the only PEG-NK4 conjugate molecules produced, contained or used are those having one, two or three PEG group(s) attached and/or are homogeneous in regard to the site of pegylation. The preparation may contain unreacted (i.e., lacking PEG group) protein. As ascertained by peptide mapping and N-terminal sequencing, one example below provides for the preparation which is at least 90% PEG-NK4 conjugate (preferably monopegylated) and at most 2 % unreacted protein.

[0020] "Monopegylated" as used herein means that NK4 is pegylated at only one group per NK4 molecule, whereby only one PEG group is attached covalently at this site and the sites of attachment can vary within the monopegylated species.

[0021] The monopegylated NK4 is at least 90% of the preparation, and most preferably, the monopegylated NK4 is 92%, or more, of the preparation. The monopegylated NK4 preparations according to the invention are therefore homogeneous enough to display the advantages of a homogeneous preparation, e.g., in a pharmaceutical application.

[0022] In a further preferred embodiment of the invention, there is provided a mixture of pegylated NK4 conjugates (especially preferred are monopegylated conjugates), wherein monopegylation has occurred at different sites (at different amino acids) of the NK4 molecules.

[0023] The PEG polymer molecules used according to the invention have a molecular weight of about 10 to 40 kDa (by "molecular weight" as used here there is to be understood the mean molecular weight of the PEG; the term "about" indicates that in said PEG preparations, some molecules will weigh more and some less than the stated molecular weight).

[0024] According to the invention, preferably a method is provided for the production of a substantially homogeneous monopegylated NK4.


[0025] Pegylation of NK4 can be performed according to the methods of the state of the art.

[0026] In a preferred embodiment of the invention, said NK4 is covalently linked to "n" poly(ethylene glycol) groups of the formula



with the -CO (i.e. carbonyl) of each poly(ethylene glycol) group forming an amide bond with one of the amino groups of NK4; R being lower alkyl; x being 2 or 3; m being from about 200 to about 950; n being from 1 to 3; and n and m being chosen together so that the molecular weight of the conjugate minus the NK4 protein is from 10 kDa to 40 kDa, preferably from 20 to 40 kDa.

[0027] More specifically, the above conjugates may be represented by formula (I)




wherein P is the group of an NK4 protein as described herein, (i.e. without the amino group or amino groups which form an amide linkage with the carbonyl shown in formula (I)); and wherein R is lower alkyl; x is 2 or 3; m is from about 200 to about 950; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the NK4 protein is from 10 kDa to 40 kDa, preferably from 20 to 40 kDa. As used herein, the given ranges of "m" merely have an orientational meaning. The ranges of "m" are determined in any case, and exactly, by the molecular weight of the PEG group(s).

[0028] As used herein, "lower alkyl" means a linear or branched alkyl group having from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl and isopropyl. In accordance with this invention, R is any lower alkyl. Conjugates in which R is methyl are preferred.

[0029] The symbol "m" represents the number of ethylene oxide groups (OCH_2CH_2) in the poly(ethylene oxide) group. A single PEG subunit of ethylene oxide has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the NK4) depends on the number "m". In the conjugates of this invention "m" is from about 200 to about 950 (corresponding to a molecular weight of about 10 kDa to about 40 kDa), preferably from about 450 to about 950 (corresponding to a molecular weight of about 20 kDa to about 40 kDa). The number m is selected such that the resulting conjugate of this invention has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4. A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. The number "m" is selected so that the molecular weight of each poly(ethylene glycol) group covalently linked to the NK4 protein is from about 10 kDa to about 40 kDa, and is preferably about 20 kDa to about 40 kDa, however the maximum molecular weight of all poly(ethylene glycol) groups together not exceeding 40 kDa.

[0030] In the conjugates of this invention, the number "n" is the number of polyethylene glycol groups covalently bound to free amino groups (including ϵ -amino groups of a lysine amino acid and/or the amino-terminal amino group) of an NK4 protein via amide linkage(s). A conjugate of this invention may have one, two, or three PEG groups per molecule of NK4. "n" is an integer ranging from 1 to 3, preferably "n" is 1 or 2, and more preferably "n" is 1.

[0031] The compound of formula (I) can be prepared, for example, from a known activated polymeric material:




in which R and m are as described above, by condensing the compound of Formula II with the NK4 protein. Compounds of formula (II) in which x is 3 are alpha-lower alkoxybutyric acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SBA). Compounds of formula (II) in which x is 2 are alpha-lower alkoxypropionic acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SPA). Any conventional method of reacting an activated ester with an amine to form an amide can be utilized. In the reaction described above, the exemplified succinimidyl ester is a leaving group causing the amide formation. The use of succinimidyl esters such as the compounds of formula II to produce conjugates with proteins are disclosed in U.S. Patent No. 5,672,662, issued September 30, 1997 (Harris, et al.).

[0032] Human NK4 contains 30 free ϵ -amino groups of 30 lysine residues. When the pegylation reagent was combined with a SBA compound of Formula II, it has been found that at a pH of about 7.0, a protein:PEG ratio of about 1:


3, and a reaction temperature of from 20-25 °C, a mixture of mono-, di-, and trace amounts of the tri-pegylated species were produced. When the protein:PEG ratio was about 1:1, primarily the mono-pegylated species is produced. By manipulating the reaction conditions (e.g., ratio of reagents, pH, temperature, protein concentration, time of reaction etc.), the relative amounts of the different pegylated species can be varied.

[0033] Monopegylated NK4 can also be produced according to the methods described in WO 94/01451. WO 94/01451 describes a method for preparing a recombinant polypeptide with a modified terminal amino acid alpha-carbon reactive group. The steps of the method involve forming the recombinant polypeptide and protecting it with one or more biologically added protecting groups at the N-terminal alpha-amine and C-terminal alpha-carboxyl. The polypeptide can then be reacted with chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified. The polypeptide is then cleaved with a cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid alpha-carbon reactive group. The unprotected terminal amino acid alpha-carbon reactive group is modified with a chemical modifying agent. The side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide. The number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of the polypeptide.

[0034] Further preferred conjugates according to the invention consist of NK4 protein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the protein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups, X is -(CH₂)_k- or -CH₂(O-CH₂-CH₂)_k-, k is from 1 to 10, Y is




or



the average molecular weight of each poly(ethylene glycol) moiety is from about 10 kDa to about 40 kDa, not exceeding 40 kDa for all poly(ethylene glycol) moieties, and the molecular weight of the conjugate is from about 62 kDa to about 92 kDa at a molecular weight of 52 kDa for NK4 polypeptide, or from about 67 kDa to about 97 kDa at a molecular weight of 57 kDa for NK4 glycoprotein.


[0035] This NK4 species may also be represented by formula (III)



wherein R may be any lower alkyl, by which is meant a linear or branched alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc. A preferred alkyl is methyl. X may be -(CH₂)_k- or -CH₂(O-CH₂-CH₂)_k-, wherein k is from 1 to about 10. Preferably, k is from 1 to about 4, more preferably, k is 1 or 2. Most preferably, X is -(CH₂)₂.


[0036] In formula III, Y is

5



or


10



15

20 preferably


25



30

more preferably

35



40

[0037] In formula (III), the number m is selected such that the resulting conjugate of formula (III) has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4. m represents the number of ethylene oxide chains in the PEG unit. A single PEG subunit of $-(OCH_2CH_2)-$ has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the NK4) depends on the number m . A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. m is therefore an integer ranging from about 200 to about 950 (corresponding to a molecular weight of from about 10 to 40 kDa), preferably m is from about 450 to about 950 (about 20 to 40 kDa).


45

50


[0038] In formula (III), the number n is the number of ϵ -amino groups of a lysine amino acid in a NK4 protein covalently bound to a PEG unit via an amide linkage. A conjugate of this invention may have one, two, or three PEG units per molecule of NK4. n is an integer ranging from 1 to 3, preferably n is 1 or 2, and more preferably n is 1.

[0039] Preferred NK4 proteins of formula (III) are represented by the formulae:


55



and




[0040] Most preferred NK4 protein products are represented by the formula:




[0041] These NK4 proteins may be prepared by

(a) covalently reacting an ϵ -amino group of a lysine amino acid of an NK4 protein represented by the formula, $\text{P} \cdot [\text{NH}_2]_n$, with a bi-functional reagent represented by the formula, $\text{Z} - \text{CO} - \text{X} - \text{S} - \text{Q}$, to form an intermediate with an amide linkage represented by the formula:



wherein P is an NK4 protein less the amino group which forms an amide linkage; n is an integer ranging from 1 to 3; Z is a reactive group, e.g. a carboxylic-NHS ester; X is $-(\text{CH}_2)_k-$ or $-\text{CH}_2(\text{O}-\text{CH}_2-\text{CH}_2)_k-$, wherein k is from 1 to about 10; and Q is a protecting group, like alkanoyl, e.g. acetyl.

(b) covalently reacting the intermediate with an amide linkage from step (a) with an activated polyethylene glycol derivative represented by the formula, $\text{W} \cdot [\text{OCH}_2\text{CH}_2]_m - \text{OR}$, to form an NK4 protein product represented by the formula:




wherein W is a sulfhydryl reactive form of Y; m is an integer ranging from about 200 to about 950; R is lower alkyl; and Y is as defined above.

[0042] In this embodiment, the bi-functional reagent is preferably N-succinimidyl-S-acetylthiopropionate or N-suc-


cinimidyl-S-acetylthioacetate, Z is preferably N-hydroxy-succinimide, and the activated polyethylene glycol derivative $W-[OCH_2CH_2]_m-OR$ is preferably selected from the group consisting of iodo-acetyl-methoxy-PEG, methoxy-PEG-vinylsulfone, and methoxy-PEG-maleimide.

[0043] In more detail, the NK4 proteins of formula (III) may be prepared by covalent linking of thiol groups to NK4 ("activation") and coupling the resulting activated NK4 with a poly(ethylene glycol) (PEG) derivative. The first step for the preparation of pegylated NK4 according to the present invention comprises covalent linking of thiol groups via NH_2 -groups of NK4. This activation of NK4 is performed with bi-functional reagents which carry a protected thiol group and an additional reactive group, such as active esters (e.g., a succinimidylester), anhydrides, esters of sulphonic acids, halogenides of carboxylic acids and sulphonic acids, respectively. The thiol group is protected by groups known in the art, e.g., acetyl groups. These bi-functional reagents are able to react with the ϵ -amino groups of the lysine amino acids by forming an amide linkage.

[0044] In a preferred embodiment the activation of the ϵ -amino lysine groups is performed by reaction with bi-functional reagents having a succinimidyl moiety. The bi-functional reagents may carry different spacer species, e.g. $-(CH_2)_k$ or $-CH_2-(O-CH_2-CH_2-)_k$ -moieties, wherein k is from 1 to about 10, preferably from 1 to about 4, and more preferably 1 or 2, and most preferably 1. Examples of these reagents are N-succinimidyl-S-acetylthiopropionate (SATP) and N-succinimidyl-S-acetylthioacetate (SATA)



Acetylthioalkyl-carboxylic-NHS-ester, like



2-(Acetylthio)-(ethoxy)_k-acetic-acid-NHS-ester

with k as defined above.

[0045] The preparation of the bi-functional reagents is known in the art. Precursors of 2-(acetylthio)-(ethoxy)_k-acetic-acid-NHS-esters are described in DE-3924705, while the derivatization to the acetylthio compound is described by March, J., Advanced Organic Chemistry (1977) 375-376. SATA is commercially available (Molecular Probes, Eugene, OR, USA and Pierce, Rockford, IL).


[0046] The number of thiol groups to be added to an NK4 molecule can be selected by adjusting the reaction parameters, i.e., the protein (NK4) concentration and the protein/bi-functional reagent ratio. Preferably, the NK4 is activated by covalently linking from 1 to 5 thiol groups per NK4 molecule, more preferably from 1.5 to 3 thiol groups per NK4 molecule. These ranges refer to the statistical distribution of the thiol group over the NK4 protein population.

[0047] The reaction is carried out, for example, in an aqueous buffer solution, pH 6.5-8.0, e.g., in 10 mM potassium phosphate, 300 mM NaCl, pH 7.3. The bi-functional reagent may be added in DMSO. After completion of the reaction, preferably after 30 minutes, the reaction is stopped by addition of lysine. Excess bifunctional reagent may be separated

by methods known in the art, e.g., by dialysis or column filtration. The average number of thiol groups added to NK4 can be determined by photometric methods described in, for example, Grasetti, D.R., and Murray, J.F. in J. Appl. Biochem. Biotechnol. 119 (1967) 41-49.


[0048] The above reaction is followed by covalent coupling of an activated polyethylene glycol (PEG) derivative. Suitable PEG derivatives are activated PEG molecules with an average molecular weight of from about 10 to about 40 kDa, more preferably from about 20 to about 40 kDa.

[0049] Activated PEG derivatives are known in the art and are described in, for example, Morpurgo, M., et al. J. Bioconj. Chem. 7 (1996) 363 ff for PEG-vinylsulfone. Linear chain and branched chain PEG species are suitable for the preparation of the compounds of Formula 1. Examples of reactive PEG reagents are iodo-acetyl-methoxy-PEG and methoxy-PEG-vinylsulfone:




[0050] The use of these iodo-activated substances is known in the art and described e.g. by Hermanson, G.T., in Bioconjugate Techniques, Academic Press, San Diego (1996) p. 147-148.


[0051] Most preferably, the PEG species are activated by maleimide using (alkoxy-PEG-maleimide), such as methoxy-PEG-maleimide (MW 10000 to 40000; Shearwater Polymers, Inc.). The structure of alkoxy-PEG-maleimide is as follows:



or



with R and m are as defined above, preferably



[0052] The coupling reaction with alkoxy-PEG-maleimide takes place after *in situ* cleavage of the thiol protecting group in an aqueous buffer solution, e.g. 10 mM potassium phosphate, 300 mM NaCl, 2 mM EDTA, pH 6.2. The cleavage of the protecting group may be performed, for example, with hydroxylamine in DMSO at 25°C, pH 6.2 for about 90 minutes. For the PEG modification the molar ratio of activated NK4/alkoxy-PEG-maleimide should be from about 1:1 to about 1:6. The reaction may be stopped by addition of cysteine and reaction of the remaining thiol (-SH) groups with N-methylmaleimide or other appropriate compounds capable of forming disulfide bonds. Because of the

reaction of any remaining active thiol groups with a protecting group such as N-methylmaleimide or other suitable protecting group, the NK4 proteins in the conjugates of this invention may contain such protecting groups. Generally the procedure described herein will produce a mixture of molecules having varying numbers of thiols protected by different numbers of the protecting group, depending on the number of activated thiol groups on the protein that were

not conjugated to PEG-maleimide.
 [0053] Whereas N-methylmaleimide forms the same type of covalent bond when used to block the remaining thiol-groups on the pegylated protein, disulfide compounds will lead in an intermolecular sulfide/disulfide exchange reaction to a disulfide bridged coupling of the blocking reagent. Preferred blocking reagents for that type of blocking reaction are oxidized glutathione (GSSG), cysteine and cystamine. Whereas with cysteine no additional net charge is introduced into the pegylated protein, the use of the blocking reagents GSSG or cystamine results in an additional negative or positive charge.

[0054] The further purification of the compounds of formula (III), including the separation of mono-, di- and tri-pegylated NK4 species, may be done by methods known in the art, e.g., column chromatography.

[0055] Usually mono-PEG conjugates of NK4 proteins are desirable because they tend to have higher activity than di-PEG conjugates.. The percentage of mono-PEG conjugates as well as the ratio of mono- and di-PEG species can be controlled by pooling broader fractions around the elution peak to decrease the percentage of mono-PEG or narrower fractions to increase the percentage of mono-PEG in the composition. About ninety percent mono-PEG conjugates is a good balance of yield and activity. Sometimes compositions in which, for example, at least ninety-two percent or at least ninety-six percent of the conjugates are mono-PEG species (n equals 1) may be desired. In an embodiment of this invention the percentage of conjugates where n is 1 is from ninety percent to ninety-six percent.

Pharmaceutical formulations

[0056] Pegylated NK4 can be administered as a mixture, or as the ion exchange chromatography or size exclusion chromatography separated different pegylated species. The compounds of the present invention can be formulated according to methods for the preparation of pharmaceutical compositions which methods are known to the person skilled in the art. For the production of such compositions, pegylated NK4 according to the invention is combined in a mixture with a pharmaceutically acceptable carrier. Such acceptable carriers are described, for example, in Remington's Pharmaceutical Sciences, 18th edition, 1990, Mack Publishing Company, edited by Oslo et al. (e.g. pp. 1435-1712). Typical compositions contain an effective amount of the substance according to the invention, for example from about 0.1 to 100 mg/ml, together with a suitable amount of a carrier. The compositions may be administered parenterally.

[0057] This invention further provides pharmaceutical compositions containing conjugates described herein in which the percentage of conjugates in which n is 1, 2 and/or 3 is preferably at least ninety percent, more preferably at least ninety-two percent.

[0058] The pharmaceutical formulations according to the invention can be prepared according to known methods in the art. Usually, solutions of pegylated NK4 are dialyzed against the buffer intended to be used in the pharmaceutical composition and the desired final protein concentration is adjusted by concentration or dilution.

[0059] Such pharmaceutical compositions may be used for administration for injection and contain an effective amount of the monopegylated NK4 together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer contents (e.g. arginine, acetate, phosphate), pH and ionic strength, additives such as detergents and solubilizing agents (e.g. Tween 80/polysorbate, pluronic F68), antioxidants (e.g. ascorbic acid, sodium metabisulfite), preservatives (Timersol, benzyl alcohol) and bulking substances (e.g. saccharose, mannitol), incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions may influence the physical state stability rate of release and clearance of the monopegylated NK4 according to the invention.

Dosages and drug concentrations

[0060] Typically, in a standard cancer treatment regimen, patients are treated with dosages in the range between 0.01 to 3 mg of pegylated NK4 per kg per day over a certain period of time, lasting from one day to about 30 days or even longer. Drug is applied as a single daily subcutaneous or i.v. bolus injection of a pharmaceutical formulation containing 0.1 to 100 mg pegylated NK4 per ml. This treatment can be combined with any standard (e.g. chemotherapeutic) treatment, by applying pegylated NK4 before, during or after the standard treatment. This results in an improved outcome compared to standard treatment alone.

[0061] The following examples, references and the sequence listing are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

SEQ ID NO:1 shows the DNA and polypeptide sequence of NK4.

SEQ ID NO:2 shows the polypeptide sequence of NK4.

Example 1

Recombinant production of NK4

[0062] NK4 for therapeutic uses may be produced by recombinant means using bacterial or eukaryotic expression systems. Suitable eukaryotic expression systems are for example engineered HeLa, BHK or preferably CHO cells. Cells engineered for NK4 production are cultivated in a suitable medium. Typically, a 1 to 5 liter cell culture is used as inoculum for a 10 liter fermenter. After 3 to 5 days, the culture in the 10 liter fermenter can be used as inoculum for the 100 liter fermenter. After additional 3 to 5 days of fermentation, this culture can be used as inoculum for the 1000 liter production fermenter. After 3 to 4 days cells are removed by filtration or centrifugation and discarded. The NK4 containing supernatant is filtered, collected and processed during purification. The purification process is described in the following example.

Example 2

Purification

[0063] Heparin-Sepharose consists of Sepharose beads to the surface of which heparin is covalently bound. Since NK4 shows a high affinity to heparin it is retained on this column and can be eluted with high salt concentrations, whereas protein contaminants and other impurities either do not bind or elute at lower salt concentrations. NK4 containing fractions, eluting at about 0.7 to 1.1 M NaCl in 50 mM Hepes pH 7.5 are collected and loaded onto a hydroxyapatite column. NK4 elutes with about 0.4 to 0.7 M potassium phosphate, pH 7.5. The resulting fractions are substantially free of contaminating proteins and can be further purified by Q-sepharose chromatography.

Example 3

Production of pegylated NK4

[0064] NK4 purified in accordance with the above mentioned procedure was used for pegylation reactions. Two of the above-mentioned suitable methods are exemplarily described.

a) Pegylation of NK4 with mPEG-SBA

[0065] Aliquots of NK4 were reacted with methoxy-PEG-SBA (10 kDa, 20 kDa, 30 kDa and 40 kDa, respectively; Shearwater Polymers, Inc., Huntsville Alabama). Reaction was carried out at a protein to reagent ratio between 1:1 and 1:5 for about 2 h at room temperature. The reaction was stopped by the addition of 30 mM Tris-buffer and samples were analyzed by SDS-PAGE or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution. The reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly mono-pegylated NK4.

b) Pegylation of NK4 with mPEG-SPA

[0066] Aliquots of NK4 were reacted with methoxy-PEG-SPA (10 kDa, 20 kDa, 30 kDa and 40 kDa, respectively; Shearwater Polymers, Inc., Huntsville Alabama). Reaction was carried out at a protein to reagent ratio between 1:1 and 1:5 for about 2 h at room temperature.

[0067] The reaction was stopped by the addition of 30 mM Tris-buffer and samples were analyzed by SDS-PAGE or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution. The reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly mono-pegylated NK4, compared to di- and tri-pegylated NK4.

Example 4**Isolation of monopegylated NK4**

- 5 [0068] Monopegylated NK4 can be separated from unpegylated, di- and tri-pegylated NK4 by running a preparative size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution, or by ion exchange chromatography. The purified protein contains predominantly the mono-pegylated species. Fractions were collected and analyzed by SDS-PAGE.

10 **Example 5****Molecular characterization of mono-pegylated NK4****a) Size exclusion chromatography**

- 15 [0069] The mono-pegylated species elutes earlier in size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia; using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution) as compared to the unmodified form. This is due to an increased hydrodynamic radius of the molecule.

20 **b) SDS-PAGE**

- [0070] In SDS-PAGE proteins are separated according to their molecular weight. Due to an increase in molecular weight by pegylation, the mono-pegylated NK4 shows a shorter migration distance as compared to the unmodified NK4. The migration distance is inversely correlated with the chain length of the PEG moiety and the number of PEG groups attached per NK4 molecule.
- 25

c) Peptide mapping

- [0071] Digestion of pegylated NK4 with sequence-specific endo-proteinases (e.g. LysC or trypsin) results in a characteristic peptide map. The resulting peptides can be separated by reversed phase chromatography and analyzed by mass spectrometry and/or N-terminal sequencing. This allows for a determination of the PEG-modified groups within the NK4 molecule.
- 30

d) Reverse phase chromatography

- 35 [0072] Pegylated NK4 can also be characterized by reversed phase chromatography. Pegylation of NK4 results in a change in retention time as compared to unmodified NK4.

Example 640 **Comparison of monopegylated, unpegylated and multi-pegylated NK4****a) Scatter assay**

- 45 [0073] MDCK cells were subconfluently grown in tissue culture plates. Cells were treated with HGF (10 ng/ml) or with combinations of HGF and NK4 (un-, mono-, or multi-pegylated). In these experiments the HGF-induced cell scattering was inhibited by the addition of a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.

50 **b) Proliferation assay**

- [0074] Inhibition of the mitogenic activity of HGF by NK4 (un-, mono-, or multi-pegylated) was determined by measuring DNA synthesis of adult rat hepatocytes in primary culture as described in Nakamura et al. (1989). In these experiments the HGF-induced cell proliferation was inhibited by the addition of a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.
- 55

c) Invasion assay

[0075] In this assay the invasive potential of tumor cells is analyzed. The assay was done essentially as described in Albini et al. (1987) using HT115 cells. Again, HGF-induced (10 ng/ml) cell invasion could be inhibited by a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.

Example 7**Activity in vivo****[0076]**

Model: Lewis Lung Carcinoma nude mouse tumor model
 1 x 10⁶ lewis lung carcinoma cells were s.c. implanted into male nude mice (BALB/c nu/nu).
 Treatment: After 4 days, one application daily of pegylated NK4 over a period of 2-4 weeks
 Dose: 1000 µg/mouse/day
 300 µg/mouse/day
 100 µg/mouse/day
 placebo
 Result: Treatment with pegylated NK4 shows a dose dependent suppression of primary tumor growth and metastasis, whereas no effect is seen in placebo treated groups.

Example 8**Pharmaceutical composition**

[0077] Suitable pharmaceutical compositions are, for example:

1 to 30 mg/ml pegylated NK4
 150 mM NaCl
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 150 mM NaCl
 0.01% Tween 80 or Tween 20 or pluronic F68
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 50 mM NaCl
 3% mannitol
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 50 mM NaCl
 3% mannitol
 0.01% Tween 80 or Tween 20 or pluronic F68
 10 mM sodium phosphate, pH 7.2

[0078] The compositions are prepared in that pegylated NK4 is dialyzed against the above mentioned buffer solution (with or without mannitol). The protein concentration is adjusted by concentration or dilution with the buffer solution. Detergent is added out of a 10% stock solution.

List of References**[0079]**

Albini et al., Cancer Res. 47 (1987) 3239-3245
 Chamow et al., Bioconjugate Chem. 5 (1994) 133-140

Date, K., et al., FEBS Letters 420 (1997) 1-6
 Date, K., et al., Oncogene 17 (1989) 3045-3054
 DE 3924705
 Delgano et al., in: Coupling of PEG to protein by activation with tresylchloride, applications in immunoaffinity cell
 5 preparation (eds. Fischer et al.), Separations using aqueous phase systems, applications in cell biology and bio-
 technology, Plenum Press, New York, 1989, pp. 211-213
 EP 0 154 316
 EP 0 401 384
 EP 0 442 724
 10 EP 0 539 167
 EP 0 822 199
 Francis et al. in Stability of Protein Pharmaceuticals: in vivo Pathways of Degradation And Strategies for Protein
 Stabilization (eds. Ahern, T., and Manning, M.C.), Plenum Press, New York, 1991
 Gaertner, H.F., and Offord, R.E., Bioconjugate Chem. 7 (1996) 38-44
 15 Grasetti, D.R., and Murray, J.F., J. Appl. Biochem. Biotechnol. 119 (1967) 41-49
 Hermanson, G.T., et al., Bioconjugate Techniques, Academic Press, San Diego, (1996) 147-148
 Kuba, K., et al., Cancer Res. 60 (2000) 6737-6743
 March, J., Advanced Organic Chemistry (1977) 375-376
 Mehvar, R., J. Pharm. Pharm. Sci. 3 (1) (2000) 125-136
 20 Miyazawa, K., et al., Biochem. Biophys. Res. Comm. 163 (1989) 967-973
 Morpurgo, M., et al., Bioconj. Chem. 7 (1996) 363
 Nakamura, T., et al., Biochem. Biophys. Res. Commun. 22 (1984) 1450-1459
 Nakamura, T., et al., Nature 342 (1989) 440-443
 Okajima, A., et al., Eur. J. Biochem. 193 (1990) 375-381
 25 Parr, C., et al., Int. J. Cancer 85 (2000) 563-570
 Remington's Pharmaceutical Sciences, 18th edition, 1990, Mack Publishing Company, edited by Oslo et al. (e.g.
 pp. 1435-1712)
 Seki, T., et al., Biochem. and Biophys. Res. Comm. 172 (1990) 321-327
 Stuart, K.A., et al., International Journal of Experimental Pathology 81 (2000) 17-30
 30 Tashiro, K., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 3200-3204
 U.S. Patent No. 4,002,531
 U.S. Patent No. 4,904,584
 U.S. Patent No. 5,252,714
 U.S. Patent No. 5,382,657
 35 U.S. Patent No. 5,672,662
 U.S. Patent No. 5,977,310
 Weidner, K.M., et al., Proc. Natl. Acad. Sci. USA 88 (1991) 7001-7005
 WO 01/02017
 WO 90/04606
 40 WO 90/07938
 WO 93/23541
 WO 94/01451

SEQUENCE LISTING

5 <110> F. HOFFMANN-LA ROCHE AG
 <120> PEG-conjugates of HGF-NK4
 <130> Case 20859
 10 <140>
 <141>
 <160> 2
 15 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 1344
 20 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 25 <222> (1)..(1344)
 <400> 1
 30 caa agg aaa aga aga aat aca att cat gaa ttc aaa aaa tca gca aag 48
 Gln Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys
 1 5 10 15
 act acc cta atc aaa ata gat cca gca ctg aag ata aaa acc aaa aaa 96
 Thr Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys
 35 20 25 30
 gtg aat act gca gac caa tgt gct aat aga tgt act agg aat aaa gga 144
 Val Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly
 35 40 45
 40 ctt cca ttc act tgc aag gct ttt gtt ttt gat aaa gca aga aaa caa 192
 Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln
 50 55 60
 45 tgc ctc tgg ttc ccc ttc aat agc atg tca agt gga gtg aaa aaa gaa 240
 Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu
 65 70 75 80
 ttt ggc cat gaa ttt gac ctc tat gaa aac aaa gac tac att aga aac 288
 50 Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn
 85 90 95
 tgc atc att ggt aaa gga cgc agc tac aag gga aca gta tct atc act 336
 55 Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr
 100 105 110

EP 1 234 583 A1

	aag agt ggc atc aaa tgt cag ccc tgg agt tcc atg ata cca cac gaa	384
	Lys Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu	
	115 120 125	
5	cac agc ttt ttg cct tcg agc tat cgg ggt aaa gac cta cag gaa aac	432
	His Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn	
	130 135 140	
10	tac tgt cga aat cct cga ggg gaa gaa ggg gga ccc tgg tgt ttc aca	480
	Tyr Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr	
	145 150 155 160	
15	agc aat cca gag gta cgc tac gaa gtc tgt gac att cct cag tgt tca	528
	Ser Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser	
	165 170 175	
20	gaa gtt gaa tgc atg acc tgc aat ggg gag agt tat cga ggt ctc atg	576
	Glu Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met	
	180 185 190	
25	gat cat aca gaa tca ggc aag att tgt cag cgc tgg gat cat cag aca	624
	Asp His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr	
	195 200 205	
30	cca cac cgg cac aaa ttc ttg cct gaa aga tat ccc gac aag ggc ttt	672
	Pro His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe	
	210 215 220	
35	gat gat aat tat tgc cgc aat ccc gat ggc cag ccg agg cca tgg tgc	720
	Asp Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys	
	225 230 235 240	
40	tat act ctt gac cct cac acc cgc tgg gag tac tgt gca att aaa aca	768
	Tyr Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr	
	245 250 255	
45	tgc gct gac aat act atg aat gac act gat gtt cct ttg gaa aca act	816
	Cys Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr	
	260 265 270	
50	gaa tgc atc caa ggt caa gga gaa ggc tac agg ggc act gtc aat acc	864
	Glu Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr	
	275 280 285	
55	att tgg aat gga att cca tgt cag cgt tgg gat tct cag tat cct cac	912
	Ile Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His	
	290 295 300	
60	gag cat gac atg act cct gaa aat ttc aag tgc aag gac cta cga gaa	960
	Glu His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu	
	305 310 315 320	
65	aat tac tgc cga aat cca gat ggg tct gaa tca ccc tgg tgt ttt acc	1008
	Asn Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr	
	325 330 335	

EP 1 234 583 A1

act gat cca aac atc cga gtt ggc tac tgc tcc caa att cca aac tgt 1056
 Thr Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys
 340 345 350

5 gat atg tca cat gga caa gat tgt tat cgt ggg aat ggc aaa aat tat 1104
 Asp Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr
 355 360 365

10 atg ggc aac tta tcc caa aca aga tct gga cta aca tgt tca atg tgg 1152
 Met Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp
 370 375 380

15 gac aag aac atg gaa gac tta cat cgt cat atc ttc tgg gaa cca gat 1200
 Asp Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp
 385 390 395 400

20 gca agt aag ctg aat gag aat tac tgc cga aat cca gat gat gat gct 1248
 Ala Ser Lys Leu Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala
 405 410 415

25 cat gga ccc tgg tgc tac acg gga aat cca ctc att cct tgg gat tat 1296
 His Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr
 420 425 430

tgc cct att tct cgt tgt gaa ggt gat acc aca cct aca ata gtc taa 1344
 Cys Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val
 435 440 445

30 <210> 2
 <211> 447
 <212> PRT
 <213> Homo sapiens

35 <400> 2
 Gln Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys
 1 5 10 15
 40 Thr Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys
 20 25 30
 Val Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly
 35 40 45
 Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln
 50 55 60
 45 Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu
 65 70 75 80
 Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn
 85 90 95

50

55

Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr
 100 105 110
 Lys Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu
 115 120 125
 His Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn
 130 135 140
 Tyr Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr
 145 150 155 160
 Ser Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser
 165 170 175
 Glu Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met
 180 185 190
 Asp His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr
 195 200 205
 Pro His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe
 210 215 220
 Asp Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys
 225 230 235 240
 Tyr Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr
 245 250 255
 Cys Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr
 260 265 270
 Glu Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr
 275 280 285
 Ile Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His
 290 295 300
 Glu His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu
 305 310 315 320
 Asn Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr
 325 330 335
 Thr Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys
 340 345 350
 Asp Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr
 355 360 365
 Met Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp
 370 375 380
 Asp Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp
 385 390 395 400
 Ala Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Ala
 405 410 415
 His Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr
 420 425 430
 Cys Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val
 435 440 445

Claims

1. A conjugate comprising an N-terminal fragment of hepatocyte growth factor (HGF/SF) consisting of the hairpin domain and the four kringle regions of the α -chain and one to three polyethylene glycol group(s), said polyethylene glycol group(s) having an overall molecular weight of from about 10 to 40 kDa.
2. A conjugate according to claim 1, **characterized in that** the polyethylene glycol group(s) has/have a molecular weight of from about 20 to 40 kDa.

3. A conjugate according to claim 1 or 2, **characterized in that** said polyethylene glycol group(s) is/are (a) mono-methoxy polyethylene glycol group(s).

5 4. A conjugate according to claims 1 to 3, **characterized in that** said polyethylene glycol group(s) is/are attached to NK4 by an acyl or alkyl linkage.

5. A conjugate according to claim 1, **characterized in that** said polyethylene glycol group(s) has/have the formula



and said -CO group forms an amide bond with one of the amino groups of said N-terminal fragment of hepatocyte growth factor, wherein

15 X is 2 or 3;
m is from about 200 to about 950;
R is lower alkyl.

6. A conjugate according to claim 5 having the formula I



wherein

25 X is 2 or 3;
m is from about 200 to about 950;
n is 2 or 3;
P is said N-terminal fragment of hepatocyte growth factor without the n amino group(s) which form amide linkage(s) with the poly(ethylene glycol) group(s).

30 7. A pharmaceutical composition comprising a conjugate of claims 1 to 6 and a pharmaceutically acceptable carrier.

8. A process for preparing a pharmaceutical composition according to claim 7.

35 9. Use of a conjugate according to claims 1 to 6 for the preparation of a medicament useful in the treatment of cancer.

10. Method for the treatment of cancer diseases, comprising the steps of administering to a patient in need thereof a pharmaceutical composition according to claim 7.

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	DATE K ET AL: "HGF/NK4 IS A SPECIFIC ANTAGONIST FOR PLEIOTROPHIC ACTIONS OF HEPATOCYTE GROWTH FACTOR" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 420, no. 1, 1997, pages 1-6, XP002920323 ISSN: 0014-5793 * abstract * * figures 1-3 * * page 5, paragraph DISCUSSION - page 6 *	1-10	A61K47/48 A61P35/00
Y	DATE K ET AL: "INHIBITION OF TUMOR GROWTH AND INVASION BY A FOUR-KRINGLE ANTAGONIST (HGF/NK4) FOR HEPATOCYTE GROWTH FACTOR" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 17, no. 23, 1998, pages 3045-3054, XP001008680 ISSN: 0950-9232 * page 3049, right-hand column, last paragraph - page 3051, left-hand column, line 5 * ----- -/-	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claim 10 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), a search has been carried out, based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		16 August 2001	Dullaart, A
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published or, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 (3.02) (PatCo7)

Application Number

EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	KUBA K ET AL: "HGF/NK4, A FOUR-KRINGLE ANTAGONIST OF HEPATOCYTE GROWTH FACTOR, IS AN ANGIOGENESIS INHIBITOR THAT SUPPRESSES TUMOR GROWTH AND METASTASIS IN MICE" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6737-6743, XP001008887 ISSN: 0008-5472 * page 6741, paragraph DISCUSSION - page 6742 *	1-10	
Y	EP 0 816 381 A (SUMITOMO PHARMA ; NAKAMURA TOSHIKAZU (JP)) 7 January 1998 (1998-01-07) * page 9, line 3 - line 8 * * examples * * claims *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	UEMATSU Y ET AL: "Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects." JOURNAL OF PHARMACEUTICAL SCIENCES, JAN 1999, VOL. 88, NO. 1, PAGE(S) 131-135, XP002175032 * abstract * * page 133, paragraph RESULTS *	1-10	
Y	WO 94 13322 A (MARCUCCI FABRIZIO ; ERBA CARLO SPA (IT); GREGORY RUTH (IT)) 23 June 1994 (1994-06-23) * page 8 * * claims *	1-10	

-/--



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	GAERTNER H F ET AL: "SITE-SPECIFIC ATTACHMENT OF FUNCTIONALIZED POLY(ETHYLENE GLYCOL) TO THE AMINO TERMINUS OF PROTEINS" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 7, no. 1, 1996, pages 38-44, XP000646874 ISSN: 1043-1802 * abstract * * page 39, scheme 1 * * page 42, right-hand column, paragraph 2 - page 43, left-hand column, line 3; figure 5 * * page 44, paragraph CONCLUSION.* ---	1-10	
Y	FRANCIS G E ET AL: "PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques." INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 68, no. 1, July 1998 (1998-07), pages 1-18, XP001010042 ISSN: 0925-5710 * abstract * * page 2 * * page 6, paragraph 4.1 * * page 7 * * page 10, paragraph 4.2 - page 12, right-hand column, line 2 * * page 13, left-hand column, last line - page 15, left-hand column, line 2 * * figure 1 * --- -/--	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	TSUTSUMI YASUO ET AL: "PEGylation of interleukin-6 effectively increases its thrombopoietic potency." THROMBOSIS AND HAEMOSTASIS, vol. 77, no. 1, 1997, pages 168-173, XP001010032 ISSN: 0340-6245 * abstract *	1-10	
Y	TSUTSUMI YASUO ET AL: "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 15, 18 July 2000 (2000-07-18), pages 8548-8553, XP002175033 July 18, 2000 ISSN: 0027-8424 * abstract * * page 8551, left-hand column, last paragraph - right-hand column, line 5; table 3 *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	HEINZERLING LUCIE ET AL: "Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient." DERMATOLOGY (BASEL), vol. 201, no. 2, 2000, pages 154-157, XP001010033 ISSN: 1018-8665 * abstract *	1-10	
	--- -/-		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	TSUTSUMI Y ET AL: "Molecular design of hybrid tumor necrosis factor-alpha III: Polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 278, no. 3, 1996, pages 1006-1011, XP001010039 ISSN: 0022-3565 * abstract * * table 2 *	1-10	
Y	REDDY K RAJENDER: "Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs." ANNALS OF PHARMACOTHERAPY, vol. 34, no. 7-8, July 2000 (2000-07), pages 915-923, XP001010043 ISSN: 1060-0280 * abstract * * table 1 * * page 919, left-hand column, paragraph - page 921, right-hand column *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 4640

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information

16-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0816381 A	07-01-1998	US 5977310 A	02-11-1999
		WO 9628475 A	19-09-1996
WO 9413322 A	23-06-1994	AT 168273 T	15-08-1998
		AU 678796 B	12-06-1997
		AU 5696894 A	04-07-1994
		CA 2150925 A	23-06-1994
		DE 69319740 D	20-08-1998
		DE 69319740 T	11-03-1999
		DK 675736 T	19-04-1999
		EP 0675736 A	11-10-1995
		ES 2121180 T	16-11-1998
		JP 8504202 T	07-05-1996
		US 6172202 B	09-01-2001

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 234 583 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
28.08.2002 Bulletin 2002/35

(51) Int Cl.7: **A61K 47/48, A61P 35/00**

(21) Application number: **01104640.6**

(22) Date of filing: **23.02.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)**

(72) Inventor: **The designation of the inventor has not
yet been filed**

(74) Representative: **Schreiner, Siegfried, Dr. et al
Roche Diagnostics GmbH,
Patent Department (TR-E),
P.O. Box 1152
82372 Penzberg (DE)**

(54) **PEG-conjugates of HGF-NK4**

(57) A conjugate comprising an N-terminal fragment of hepatocyte growth factor (HGF/SF) consisting of the hairpin domain and the four kringle regions of the α -chain and one to three polyethylene glycol group(s), said polyethylene glycol group(s) having an overall mo-

lecular weight of from about 10 to 40 kDa, has improved properties and is a useful therapeutic agent for tumor treatment.

EP 1 234 583 A1

Description

[0001] This invention relates to conjugates of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) with polyethylene glycol (PEG), pharmaceutical compositions thereof, methods for the production and methods for use.

Background of the Invention

[0002] Hepatocyte growth factor (HGF/SF) is a polypeptide identified and purified by Nakamura, T., et al., *Biochem. Biophys. Res. Commun.* 22 (1984) 1450-1459. It was further found that hepatocyte growth factor is identical to scatter factor (SF), Weidner, K.M., et al., *Proc. Natl. Acad. Sci. USA* 88 (1991) 7001-7005. HGF is a glycoprotein involved in the development of a number of cellular phenotypes including proliferation, mitogenesis, formation of branching tubules and, in the case of tumor cells, invasion and metastasis. For a status review, see Stuart, K.A., et al., *International Journal of Experimental Pathology* 81 (2000) 17-30.

[0003] Both rat HGF and human HGF have been sequenced and cloned (Miyazawa, K. et al., *Biochem. Biophys. Res. Comm.* 163 (1989) 967-973; Nakamura, T., et al., *Nature* 342 (1989) 440-443; Seki, T., et al., *Biochem. and Biophys. Res. Comm.* 172 (1990) 321-327; Tashiro, K., et al., *Proc. Natl. Acad. Sci. USA* 87 (1990) 3200-3204; Okajima, A., et al., *Eur. J. Biochem.* 193 (1990) 375-381).

[0004] U.S. Patent No. 5,977,310 describes PEG-modified HGF. Such PEG-modified HGF has a prolonged clearance in vivo and has the same physiological activity as HGF. However, according to U.S. Patent No. 5,977,310, it is only possible to prolong the half life of HGF from 59.2 minutes to 76.7 minutes or 95.6 minutes, respectively (see Example 5 of U.S. Patent No. 5,977,310). It is further suggested in this patent that the molar amount of the PEG reagent may be selected from the range of from 5 to 100 times of the molar weight of HGF. In the case of modifying an amino group of lysine or the N-terminus of protein, a preferred molar range of the PEG reagent is of from 10 to 25 times of the molar weight of HGF. The molecular weight of the attached PEG chain was about 10 kDa.

[0005] It was further found that an HGF/SF fragment, termed NK4, consisting of the N-terminal hairpin domain and the four kringle domains of HGF/SF has pharmacological properties that are completely different from those of HGF/SF, and is an antagonist to the influence of HGF/SF on the motility and the invasion of colon cancer cells, and is, in addition, an angiogenesis inhibitor that suppresses tumor growth and metastasis (Parr, C., et al., *Int. J. Cancer* 85 (2000) 563-570; Kuba, K., et al., *Cancer Res.* 60 (2000) 6737-6743; Date, K., et al., *FEBS Letters* 420 (1997) 1-6; Date, K., et al., *Oncogene* 17 (1999) 3045-3054).

[0006] According to the state of the art, NK4 is, however, not a substance that appears suitable for easy therapeutic use in humans. As emerges from Kuba, K., et al., *Cancer Res.* 60 (2000) 6737-6743, in animal experiments, for detecting an effect of NK4 on lung metastases, NK4 had to be infused continuously over a period of two weeks.

[0007] It is known that the attachment of polymers to certain polypeptides may increase the serum half life of such polypeptides. This was found, for example, for pegylated Interleukin-6 (EP 0 442 724) or Interleukin-2 (WO 90/07938) and erythropoietin (WO 01/02017). However, the attachment of polyethylene glycol and other polymers did not necessarily lead to prolongation of their serum half lives. It is known, for example, that the conjugation of different polyethylene glycols to Interleukin-8, G-CSF and other interleukins results in the production of molecules with impaired properties (Gaertner, H.F., and Offord, R.E., *Bioconjugate Chem.* 7 (1996) 38-44; Mehvar, R., *J. Pharm. Pharm. Sci.* 3 (1) (2000) 125-136). Thus, the outcome of a pegylation of a polypeptide is highly unpredictable.

[0008] It was an object of the present invention to find an improved pharmaceutical composition for NK4, which composition can be administered as only a few, bolus applications per week and which is capable of suppressing tumor growth, angiogenesis and metastasis.

Summary of the Invention

[0009] The present invention provides NK4 conjugates consisting of NK4 being covalently linked to from one to three polyethylene glycol (PEG) groups (pegylated NK4).

[0010] It has been found, surprisingly, that pegylated, preferably monopegylated, NK4 according to the invention has superior properties in regard to the therapeutic applicability.

[0011] The invention further comprises a method for the production of pegylated NK4.

[0012] The invention further comprises pharmaceutical compositions containing pegylated NK4.

[0013] The invention further comprises methods for the production of pharmaceutical compositions containing pegylated NK4.

[0014] The invention further comprises methods for the treatment of human cancer (e.g. breast, lung, prostate or colon cancer) characterized in that a pharmaceutically effective amount of pegylated NK4 is administered in one to seven bolus applications per week to the patient in need thereof.

Detailed Description of the Invention

[0015] Human HGF is a disulfide-linked heterodimer, which can be cleaved in an α -subunit of 463 amino acids and a β -subunit of 234 amino acids, by cleavage between amino acids R494 and V495. The N-terminus of the α -chain is preceded by 31 amino acids started with a methionine group. This segment includes a signal sequence of 31 amino acids. The α -chain starts at amino acid 32 and contains four kringle domains. The so-called "hairpin domain" consists of amino acids 70-96. The kringle 1 domain consists of amino acids 128-206. The kringle 2 domain consists of amino acids 211-288, the kringle 3 domain consists of amino acids 305-383, and the kringle 4 domain consists of amino acids 391-469 of the α -chain, approximately. There exist variations of these sequences, essentially not affecting the biological properties of NK4 (especially not affecting its activities antagonistic to HGF and its antiangiogenic activities), which variations are described, for example, in WO 93/23541. Also the length of NK4 can vary within a few amino acids as long as its biological properties are not affected.

[0016] NK4 is composed of the N-terminal 447 amino acids of the HGF/SF α -chain, which includes the above-mentioned four kringle domains. It can be produced recombinantly, either by the production of recombinant human HGF/SF and digestion with elastase (Date, K., FEBS Letters 420 (1997) 1-6) or by recombinant expression of an NK4 encoding nucleic acid in appropriate host cells, as described below. NK4 glycoprotein has a molecular weight of about 57 kDa (52 kDa for the polypeptide part alone) and has the in vivo biological activity of causing inhibition of tumor growth, angiogenesis and/or metastasis.

[0017] The invention provides pegylated forms of NK4 with improved properties. Such pegylated NK4 contains one to three PEG groups attached thereto, whereby the overall molecular weight of all PEG groups in the conjugate is 10 to 40 kDa, preferably 20 to 40 kDa. This implies that the pegylated forms of NK4 according to the invention comprise, for example,

- monopegylated NK4, the PEG group having a molecular weight of 10, 20, 30 or 40 kDa;
- dipegylated NK4, the PEG groups having a molecular weight of 10 or 20 kDa each;
- tripegylated NK4, the PEG groups having a molecular weight of 10 kDa each, or mixtures thereof.

[0018] "Pegylated NK4" as used herein therefore means that NK4 has attached covalently one, two or three polyethylene glycol groups. The groups can be attached at different sites of the NK4 molecule, preferably, however, at the most reactive sites, e.g., the lysine side chains. Due to the synthesis method used, "pegylated NK4" can consist of a mixture of mono-, di- and/or tripegylated NK4, whereby the sites of pegylations can be different in different molecules or can be substantially homogeneous in regard to the amount of polyethylene glycol side chains per molecule and/or the site of pegylation in the molecule. Isolation and purification of such homogeneous preparations of pegylated NK4 can be performed by usual purification methods, preferably size exclusion chromatography.

[0019] "Substantially homogeneous" as used herein means that the only PEG-NK4 conjugate molecules produced, contained or used are those having one, two or three PEG group(s) attached and/or are homogeneous in regard to the site of pegylation. The preparation may contain unreacted (i.e., lacking PEG group) protein. As ascertained by peptide mapping and N-terminal sequencing, one example below provides for the preparation which is at least 90% PEG-NK4 conjugate (preferably monopegylated) and at most 2 % unreacted protein.

[0020] "Monopegylated" as used herein means that NK4 is pegylated at only one group per NK4 molecule, whereby only one PEG group is attached covalently at this site and the sites of attachment can vary within the monopegylated species.

[0021] The monopegylated NK4 is at least 90% of the preparation, and most preferably, the monopegylated NK4 is 92%, or more, of the preparation. The monopegylated NK4 preparations according to the invention are therefore homogeneous enough to display the advantages of a homogeneous preparation, e.g., in a pharmaceutical application.

[0022] In a further preferred embodiment of the invention, there is provided a mixture of pegylated NK4 conjugates (especially preferred are monopegylated conjugates), wherein monopegylation has occurred at different sites (at different amino acids) of the NK4 molecules.

[0023] The PEG polymer molecules used according to the invention have a molecular weight of about 10 to 40 kDa (by "molecular weight" as used here there is to be understood the mean molecular weight of the PEG; the term "about" indicates that in said PEG preparations, some molecules will weigh more and some less than the stated molecular weight).

[0024] According to the invention, preferably a method is provided for the production of a substantially homogeneous monopegylated NK4.

[0025] Pegylation of NK4 can be performed according to the methods of the state of the art.

[0026] In a preferred embodiment of the invention, said NK4 is covalently linked to "n" poly(ethylene glycol) groups of the formula



with the -CO (i.e. carbonyl) of each poly(ethylene glycol) group forming an amide bond with one of the amino groups of NK4; R being lower alkyl; x being 2 or 3; m being from about 200 to about 950; n being from 1 to 3; and n and m being chosen together so that the molecular weight of the conjugate minus the NK4 protein is from 10 kDa to 40 kDa, preferably from 20 to 40 kDa.

[0027] More specifically, the above conjugates may be represented by formula (I)




wherein P is the group of an NK4 protein as described herein, (i.e. without the amino group or amino groups which form an amide linkage with the carbonyl shown in formula (I); and wherein R is lower alkyl; x is 2 or 3; m is from about 200 to about 950; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the NK4 protein is from 10 kDa to 40 kDa, preferably from 20 to 40 kDa. As used herein, the given ranges of "m" merely have an orientational meaning. The ranges of "m" are determined in any case, and exactly, by the molecular weight of the PEG group(s).

[0028] As used herein, "lower alkyl" means a linear or branched alkyl group having from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl and isopropyl. In accordance with this invention, R is any lower alkyl. Conjugates in which R is methyl are preferred.

[0029] The symbol "m" represents the number of ethylene oxide groups (OCH_2CH_2) in the poly(ethylene oxide) group. A single PEG subunit of ethylene oxide has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the NK4) depends on the number "m". In the conjugates of this invention "m" is from about 200 to about 950 (corresponding to a molecular weight of about 10 kDa to about 40 kDa), preferably from about 450 to about 950 (corresponding to a molecular weight of about 20 kDa to about 40 kDa). The number m is selected such that the resulting conjugate of this invention has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4. A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. The number "m" is selected so that the molecular weight of each poly(ethylene glycol) group covalently linked to the NK4 protein is from about 10 kDa to about 40 kDa, and is preferably about 20 kDa to about 40 kDa, however the maximum molecular weight of all poly(ethylene glycol) groups together not exceeding 40 kDa.

[0030] In the conjugates of this invention, the number "n" is the number of polyethylene glycol groups covalently bound to free amino groups (including ϵ -amino groups of a lysine amino acid and/or the amino-terminal amino group) of an NK4 protein via amide linkage(s). A conjugate of this invention may have one, two, or three PEG groups per molecule of NK4. "n" is an integer ranging from 1 to 3, preferably "n" is 1 or 2, and more preferably "n" is 1.

[0031] The compound of formula (I) can be prepared, for example, from a known activated polymeric material:




in which R and m are as described above, by condensing the compound of Formula II with the NK4 protein. Compounds of formula (II) in which x is 3 are alpha-lower alkoxybutyric acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SBA). Compounds of formula (II) in which x is 2 are alpha-lower alkoxypropionic acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SPA). Any conventional method of reacting an activated ester with an amine to form an amide can be utilized. In the reaction described above, the exemplified succinimidyl ester is a leaving group causing the amide formation. The use of succinimidyl esters such as the compounds of formula II to produce conjugates with proteins are disclosed in U.S. Patent No. 5,672,662, issued September 30, 1997 (Harris, et al.).

[0032] Human NK4 contains 30 free ϵ -amino groups of 30 lysine residues. When the pegylation reagent was combined with a SBA compound of Formula II, it has been found that at a pH of about 7.0, a protein:PEG ratio of about 1:


3, and a reaction temperature of from 20-25 °C, a mixture of mono-, di-, and trace amounts of the tri-pegylated species were produced. When the protein:PEG ratio was about 1:1, primarily the mono-pegylated species is produced. By manipulating the reaction conditions (e.g., ratio of reagents, pH, temperature, protein concentration, time of reaction etc.), the relative amounts of the different pegylated species can be varied.

[0033] Monopegylated NK4 can also be produced according to the methods described in WO 94/01451. WO 94/01451 describes a method for preparing a recombinant polypeptide with a modified terminal amino acid alpha-carbon reactive group. The steps of the method involve forming the recombinant polypeptide and protecting it with one or more biologically added protecting groups at the N-terminal alpha-amine and C-terminal alpha-carboxyl. The polypeptide can then be reacted with chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified. The polypeptide is then cleaved with a cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid alpha-carbon reactive group. The unprotected terminal amino acid alpha-carbon reactive group is modified with a chemical modifying agent. The side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide. The number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of the polypeptide.

[0034] Further preferred conjugates according to the invention consist of NK4 protein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the protein via a linker of the formula $-C(O)-X-S-Y-$ with the $C(O)$ of the linker forming an amide bond with one of said amino groups, X is $-(CH_2)_k-$ or $-CH_2(O-CH_2-CH_2)_k-$, k is from 1 to 10, Y is




or



the average molecular weight of each poly(ethylene glycol) moiety is from about 10 kDa to about 40 kDa, not exceeding 40 kDa for all poly(ethylene glycol) moieties, and the molecular weight of the conjugate is from about 62 kDa to about 92 kDa at a molecular weight of 52 kDa for NK4 polypeptide, or from about 67 kDa to about 97 kDa at a molecular weight of 57 kDa for NK4 glycoprotein.


[0035] This NK4 species may also be represented by formula (III)



wherein R may be any lower alkyl, by which is meant a linear or branched alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc. A preferred alkyl is methyl. X may be $-(CH_2)_k-$ or $-CH_2(O-CH_2-CH_2)_k-$, wherein k is from 1 to about 10. Preferably, k is from 1 to about 4, more preferably, k is 1 or 2. Most preferably, X is $-(CH_2)_2-$.


[0036] In formula III, Y is

5



or


10



15

20 preferably


25



30

more preferably

35



40

[0037] In formula (III), the number m is selected such that the resulting conjugate of formula (III) has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4. m represents the number of ethylene oxide chains in the PEG unit. A single PEG subunit of $-(OCH_2CH_2)-$ has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the NK4) depends on the number m . A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. m is therefore an integer ranging from about 200 to about 950 (corresponding to a molecular weight of from about 10 to 40 kDa), preferably m is from about 450 to about 950 (about 20 to 40 kDa).

45


50

[0038] In formula (III), the number n is the number of ϵ -amino groups of a lysine amino acid in a NK4 protein covalently bound to a PEG unit via an amide linkage. A conjugate of this invention may have one, two, or three PEG units per molecule of NK4. n is an integer ranging from 1 to 3, preferably n is 1 or 2, and more preferably n is 1.

[0039] Preferred NK4 proteins of formula (III) are represented by the formulae:

55


5



and


10

15



20 [0040] Most preferred NK4 protein products are represented by the formula:

25




30

[0041] These NK4 proteins may be prepared by

35

(a) covalently reacting an ϵ -amino group of a lysine amino acid of an NK4 protein represented by the formula, $\text{P} \cdot [\text{NH}_2]_n$, with a bi-functional reagent represented by the formula, $\text{Z} \cdot \text{CO} \cdot \text{X} \cdot \text{S} \cdot \text{Q}$, to form an intermediate with an amide linkage represented by the formula:




40

wherein P is an NK4 protein less the amino group which forms an amide linkage; n is an integer ranging from 1 to 3; Z is a reactive group, e.g. a carboxylic-NHS ester; X is $-(\text{CH}_2)_k$ - or $-\text{CH}_2(\text{O} \cdot \text{CH}_2 \cdot \text{CH}_2)_k$ -, wherein k is from 1 to about 10; and Q is a protecting group, like alkanoyl, e.g. acetyl.

45

(b) covalently reacting the intermediate with an amide linkage from step (a) with an activated polyethylene glycol derivative represented by the formula, $\text{W} \cdot [\text{OCH}_2\text{CH}_2]_m \cdot \text{OR}$, to form an NK4 protein product represented by the formula:

50



55


wherein W is a sulfhydryl reactive form of Y; m is an integer ranging from about 200 to about 950; R is lower alkyl; and Y is as defined above.

[0042] In this embodiment, the bi-functional reagent is preferably N-succinimidyl-S-acetylthiopropionate or N-suc-


cinimidyl-S-acetylthioacetate, Z is preferably N-hydroxy-succinimide, and the activated polyethylene glycol derivative $W-[OCH_2CH_2]_m-OR$ is preferably selected from the group consisting of iodo-acetyl-methoxy-PEG, methoxy-PEG-vinylsulfone, and methoxy-PEG-maleimide.

[0043] In more detail, the NK4 proteins of formula (III) may be prepared by covalent linking of thiol groups to NK4 ("activation") and coupling the resulting activated NK4 with a poly(ethylene glycol) (PEG) derivative. The first step for the preparation of pegylated NK4 according to the present invention comprises covalent linking of thiol groups via NH_2 -groups of NK4. This activation of NK4 is performed with bi-functional reagents which carry a protected thiol group and an additional reactive group, such as active esters (e.g., a succinimidylester), anhydrides, esters of sulphonic acids, halogenides of carboxylic acids and sulphonic acids, respectively. The thiol group is protected by groups known in the art, e.g., acetyl groups. These bi-functional reagents are able to react with the ϵ -amino groups of the lysine amino acids by forming an amide linkage.

[0044] In a preferred embodiment the activation of the ϵ -amino lysine groups is performed by reaction with bi-functional reagents having a succinimidyl moiety. The bi-functional reagents may carry different spacer species, e.g. $-(CH_2)_k$ or $-CH_2-(O-CH_2-CH_2-)_k$ -moieties, wherein k is from 1 to about 10, preferably from 1 to about 4, and more preferably 1 or 2, and most preferably 1. Examples of these reagents are N-succinimidyl-S-acetylthiopropionate (SATP) and N-succinimidyl-S-acetylthioacetate (SATA)




Acetylthioalkyl-carboxylic-NHS-ester, like



SATP

SATA



2-(Acetylthio)-(ethoxy)_k-acetic-acid-NHS-ester

with k as defined above.

[0045] The preparation of the bi-functional reagents is known in the art. Precursors of 2-(acetylthio)-(ethoxy)_k-acetic-acid-NHS-esters are described in DE-3924705, while the derivatization to the acetylthio compound is described by March, J., Advanced Organic Chemistry (1977) 375-376. SATA is commercially available (Molecular Probes, Eugene, OR, USA and Pierce, Rockford, IL).


[0046] The number of thiol groups to be added to an NK4 molecule can be selected by adjusting the reaction parameters, i.e., the protein (NK4) concentration and the protein/bi-functional reagent ratio. Preferably, the NK4 is activated by covalently linking from 1 to 5 thiol groups per NK4 molecule, more preferably from 1.5 to 3 thiol groups per NK4 molecule. These ranges refer to the statistical distribution of the thiol group over the NK4 protein population.

[0047] The reaction is carried out, for example, in an aqueous buffer solution, pH 6.5-8.0, e.g., in 10 mM potassium phosphate, 300 mM NaCl, pH 7.3. The bi-functional reagent may be added in DMSO. After completion of the reaction, preferably after 30 minutes, the reaction is stopped by addition of lysine. Excess bifunctional reagent may be separated

by methods known in the art, e.g., by dialysis or column filtration. The average number of thiol groups added to NK4 can be determined by photometric methods described in, for example, Grasetti, D.R., and Murray, J.F. in J. Appl. Biochem. Biotechnol. 119 (1967) 41-49.


[0048] The above reaction is followed by covalent coupling of an activated polyethylene glycol (PEG) derivative. Suitable PEG derivatives are activated PEG molecules with an average molecular weight of from about 10 to about 40 kDa, more preferably from about 20 to about 40 kDa.

[0049] Activated PEG derivatives are known in the art and are described in, for example, Morpurgo, M., et al. J. Bioconj. Chem. 7 (1996) 363 ff for PEG-vinylsulfone. Linear chain and branched chain PEG species are suitable for the preparation of the compounds of Formula 1. Examples of reactive PEG reagents are iodo-acetyl-methoxy-PEG and methoxy-PEG-vinylsulfone:




[0050] The use of these iodo-activated substances is known in the art and described e.g. by Hermanson, G.T., in Bioconjugate Techniques, Academic Press, San Diego (1996) p. 147-148.


[0051] Most preferably, the PEG species are activated by maleimide using (alkoxy-PEG-maleimide), such as methoxy-PEG-maleimide (MW 10000 to 40000; Shearwater Polymers, Inc.). The structure of alkoxy-PEG-maleimide is as follows:



or



with R and m are as defined above, preferably



[0052] The coupling reaction with alkoxy-PEG-maleimide takes place after *in situ* cleavage of the thiol protecting group in an aqueous buffer solution, e.g. 10 mM potassium phosphate, 300 mM NaCl, 2 mM EDTA, pH 6.2. The cleavage of the protecting group may be performed, for example, with hydroxylamine in DMSO at 25°C, pH 6.2 for about 90 minutes. For the PEG modification the molar ratio of activated NK4/alkoxy-PEG-maleimide should be from about 1:1 to about 1:6. The reaction may be stopped by addition of cysteine and reaction of the remaining thiol (-SH) groups with N-methylmaleimide or other appropriate compounds capable of forming disulfide bonds. Because of the

reaction of any remaining active thiol groups with a protecting group such as N-methylmaleimide or other suitable protecting group, the NK4 proteins in the conjugates of this invention may contain such protecting groups. Generally the procedure described herein will produce a mixture of molecules having varying numbers of thiols protected by different numbers of the protecting group, depending on the number of activated thiol groups on the protein that were not conjugated to PEG-maleimide.

[0053] Whereas N-methylmaleimide forms the same type of covalent bond when used to block the remaining thiol-groups on the pegylated protein, disulfide compounds will lead in an intermolecular sulfide/disulfide exchange reaction to a disulfide bridged coupling of the blocking reagent. Preferred blocking reagents for that type of blocking reaction are oxidized glutathione (GSSG), cysteine and cystamine. Whereas with cysteine no additional net charge is introduced into the pegylated protein, the use of the blocking reagents GSSG or cystamine results in an additional negative or positive charge.

[0054] The further purification of the compounds of formula (III), including the separation of mono-, di- and tri-pegylated NK4 species, may be done by methods known in the art, e.g., column chromatography.

[0055] Usually mono-PEG conjugates of NK4 proteins are desirable because they tend to have higher activity than di-PEG conjugates. The percentage of mono-PEG conjugates as well as the ratio of mono- and di-PEG species can be controlled by pooling broader fractions around the elution peak to decrease the percentage of mono-PEG or narrower fractions to increase the percentage of mono-PEG in the composition. About ninety percent mono-PEG conjugates is a good balance of yield and activity. Sometimes compositions in which, for example, at least ninety-two percent or at least ninety-six percent of the conjugates are mono-PEG species (n equals 1) may be desired. In an embodiment of this invention the percentage of conjugates where n is 1 is from ninety percent to ninety-six percent.

Pharmaceutical formulations

[0056] Pegylated NK4 can be administered as a mixture, or as the ion exchange chromatography or size exclusion chromatography separated different pegylated species. The compounds of the present invention can be formulated according to methods for the preparation of pharmaceutical compositions which methods are known to the person skilled in the art. For the production of such compositions, pegylated NK4 according to the invention is combined in a mixture with a pharmaceutically acceptable carrier. Such acceptable carriers are described, for example, in Remington's Pharmaceutical Sciences, 18th edition, 1990, Mack Publishing Company, edited by Oslo et al. (e.g. pp. 1435-1712). Typical compositions contain an effective amount of the substance according to the invention, for example from about 0.1 to 100 mg/ml, together with a suitable amount of a carrier. The compositions may be administered parenterally.

[0057] This invention further provides pharmaceutical compositions containing conjugates described herein in which the percentage of conjugates in which n is 1, 2 and/or 3 is preferably at least ninety percent, more preferably at least ninety-two percent.

[0058] The pharmaceutical formulations according to the invention can be prepared according to known methods in the art. Usually, solutions of pegylated NK4 are dialyzed against the buffer intended to be used in the pharmaceutical composition and the desired final protein concentration is adjusted by concentration or dilution.

[0059] Such pharmaceutical compositions may be used for administration for injection and contain an effective amount of the monopegylated NK4 together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer contents (e.g. arginine, acetate, phosphate), pH and ionic strength, additives such as detergents and solubilizing agents (e.g. Tween 80/polysorbate, pluronic F68), antioxidants (e.g. ascorbic acid, sodium metabisulfite), preservatives (Timersol, benzyl alcohol) and bulking substances (e.g. saccharose, mannitol), incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions may influence the physical state stability rate of release and clearance of the monopegylated NK4 according to the invention.

Dosages and drug concentrations

[0060] Typically, in a standard cancer treatment regimen, patients are treated with dosages in the range between 0.01 to 3 mg of pegylated NK4 per kg per day over a certain period of time, lasting from one day to about 30 days or even longer. Drug is applied as a single daily subcutaneous or i.v. bolus injection of a pharmaceutical formulation containing 0.1 to 100 mg pegylated NK4 per ml. This treatment can be combined with any standard (e.g. chemotherapeutic) treatment, by applying pegylated NK4 before, during or after the standard treatment. This results in an improved outcome compared to standard treatment alone.

[0061] The following examples, references and the sequence listing are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

SEQ ID NO:1 shows the DNA and polypeptide sequence of NK4.
 SEQ ID NO:2 shows the polypeptide sequence of NK4.

Example 1

Recombinant production of NK4

[0062] NK4 for therapeutic uses may be produced by recombinant means using bacterial or eukaryotic expression systems. Suitable eukaryotic expression systems are for example engineered HeLa, BHK or preferably CHO cells. Cells engineered for NK4 production are cultivated in a suitable medium. Typically, a 1 to 5 liter cell culture is used as inoculum for a 10 liter fermenter. After 3 to 5 days, the culture in the 10 liter fermenter can be used as inoculum for the 100 liter fermenter. After additional 3 to 5 days of fermentation, this culture can be used as inoculum for the 1000 liter production fermenter. After 3 to 4 days cells are removed by filtration or centrifugation and discarded. The NK4 containing supernatant is filtered, collected and processed during purification. The purification process is described in the following example.

Example 2

Purification

[0063] Heparin-Sepharose consists of Sepharose beads to the surface of which heparin is covalently bound. Since NK4 shows a high affinity to heparin it is retained on this column and can be eluted with high salt concentrations, whereas protein contaminants and other impurities either do not bind or elute at lower salt concentrations. NK4 containing fractions, eluting at about 0.7 to 1.1 M NaCl in 50 mM Hepes pH 7.5 are collected and loaded onto a hydroxyapatite column. NK4 elutes with about 0.4 to 0.7 M potassium phosphate, pH 7.5. The resulting fractions are substantially free of contaminating proteins and can be further purified by Q-sepharose chromatography.

Example 3

Production of pegylated NK4

[0064] NK4 purified in accordance with the above mentioned procedure was used for pegylation reactions. Two of the above-mentioned suitable methods are exemplarily described.

a) Pegylation of NK4 with mPEG-SBA

[0065] Aliquots of NK4 were reacted with methoxy-PEG-SBA (10 kDa, 20 kDa, 30 kDa and 40 kDa, respectively; Shearwater Polymers, Inc., Huntsville Alabama). Reaction was carried out at a protein to reagent ratio between 1:1 and 1:5 for about 2 h at room temperature. The reaction was stopped by the addition of 30 mM Tris-buffer and samples were analyzed by SDS-PAGE or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution. The reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly mono-pegylated NK4.

b) Pegylation of NK4 with mPEG-SPA

[0066] Aliquots of NK4 were reacted with methoxy-PEG-SPA (10 kDa, 20 kDa, 30 kDa and 40 kDa, respectively; Shearwater Polymers, Inc., Huntsville Alabama). Reaction was carried out at a protein to reagent ratio between 1:1 and 1:5 for about 2 h at room temperature.

[0067] The reaction was stopped by the addition of 30 mM Tris-buffer and samples were analyzed by SDS-PAGE or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution. The reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly mono-pegylated NK4, compared to di- and tri-pegylated NK4.

Example 4**Isolation of monopegylated NK4**

- 5 [0068] Monopegylated NK4 can be separated from unpegylated, di- and tri-pegylated NK4 by running a preparative size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia) using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution, or by ion exchange chromatography. The purified protein contains predominantly the mono-pegylated species. Fractions were collected and analyzed by SDS-PAGE.

10 **Example 5****Molecular characterization of mono-pegylated NK4****a) Size exclusion chromatography**

- 15 [0069] The mono-pegylated species elutes earlier in size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia; using as buffer solution 50 mmol/l Na phosphate, 300 mmol/l NaCl, pH 6.8, for equilibration and elution) as compared to the unmodified form. This is due to an increased hydrodynamic radius of the molecule.

20 **b) SDS-PAGE**

- [0070] In SDS-PAGE proteins are separated according to their molecular weight. Due to an increase in molecular weight by pegylation, the mono-pegylated NK4 shows a shorter migration distance as compared to the unmodified NK4. The migration distance is inversely correlated with the chain length of the PEG moiety and the number of PEG groups attached per NK4 molecule.
- 25

c) Peptide mapping

- [0071] Digestion of pegylated NK4 with sequence-specific endo-proteinases (e.g. LysC or trypsin) results in a characteristic peptide map. The resulting peptides can be separated by reversed phase chromatography and analyzed by mass spectrometry and/or N-terminal sequencing. This allows for a determination of the PEG-modified groups within the NK4 molecule.
- 30

d) Reverse phase chromatography

- 35 [0072] Pegylated NK4 can also be characterized by reversed phase chromatography. Pegylation of NK4 results in a change in retention time as compared to unmodified NK4.

Example 640 **Comparison of monopegylated, unpegylated and multi-pegylated NK4****a) Scatter assay**

- 45 [0073] MDCK cells were subconfluently grown in tissue culture plates. Cells were treated with HGF (10 ng/ml) or with combinations of HGF and NK4 (un-, mono-, or multi-pegylated). In these experiments the HGF-induced cell scattering was inhibited by the addition of a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.

50 **b) Proliferation assay**

- [0074] Inhibition of the mitogenic activity of HGF by NK4 (un-, mono-, or multi-pegylated) was determined by measuring DNA synthesis of adult rat hepatocytes in primary culture as described in Nakamura et al. (1989). In these experiments the HGF-induced cell proliferation was inhibited by the addition of a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.
- 55

c) Invasion assay

[0075] In this assay the invasive potential of tumor cells is analyzed. The assay was done essentially as described in Albini et al. (1987) using HT115 cells. Again, HGF-induced (10 ng/ml) cell invasion could be inhibited by a 10 to 1000-fold molar excess of NK4 (un-, mono-, or multi-pegylated), showing the functional activity of pegylated NK4.

Example 7**Activity in vivo****[0076]**

Model: Lewis Lung Carcinoma nude mouse tumor model
 1 x 10⁶ lewis lung carcinoma cells were s.c. implanted into male nude mice (BALB/c nu/nu).
 Treatment: After 4 days, one application daily of pegylated NK4 over a period of 2-4 weeks
 Dose: 1000 µg/mouse/day
 300 µg/mouse/day
 100 µg/mouse/day
 placebo
 Result: Treatment with pegylated NK4 shows a dose dependent suppression of primary tumor growth and metastasis, whereas no effect is seen in placebo treated groups.

Example 8**Pharmaceutical composition**

[0077] Suitable pharmaceutical compositions are, for example:

1 to 30 mg/ml pegylated NK4
 150 mM NaCl
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 150 mM NaCl
 0.01% Tween 80 or Tween 20 or pluronic F68
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 50 mM NaCl
 3% mannitol
 10 mM sodium phosphate, pH 7.2

1 to 30 mg/ml pegylated NK4
 50 mM NaCl
 3% mannitol
 0.01% Tween 80 or Tween 20 or pluronic F68
 10 mM sodium phosphate, pH 7.2

[0078] The compositions are prepared in that pegylated NK4 is dialyzed against the above mentioned buffer solution (with or without mannitol). The protein concentration is adjusted by concentration or dilution with the buffer solution. Detergent is added out of a 10% stock solution.

List of References**[0079]**

Albini et al., Cancer Res. 47 (1987) 3239-3245
 Chamow et al., Bioconjugate Chem. 5 (1994) 133-140

- Date, K., et al., FEBS Letters 420 (1997) 1-6 .
 Date, K., et al., Oncogene 17 (1989) 3045-3054
 DE 3924705
 Delgano et al., in: Coupling of PEG to protein by activation with tresylchloride, applications in immunoaffinity cell
 5 preparation (eds. Fischer et al.), Separations using aqueous phase systems, applications in cell biology and bio-
 technology, Plenum Press, New York, 1989, pp. 211-213
 EP 0 154 316
 EP 0 401 384
 EP 0 442 724
 10 EP 0 539 167
 EP 0 822 199
 Francis et al. in Stability of Protein Pharmaceuticals: in vivo Pathways of Degradation And Strategies for Protein
 Stabilization (eds. Ahern, T., and Manning, M.C.), Plenum Press, New York, 1991
 Gaertner, H.F., and Offord, R.E., Bioconjugate Chem. 7 (1996) 38-44
 15 Grasetti, D.R., and Murray, J.F., J. Appl. Biochem. Biotechnol. 119 (1967) 41-49
 Hermanson, G.T., et al., Bioconjugate Techniques, Academic Press, San Diego, (1996) 147-148
 Kuba, K., et al., Cancer Res. 60 (2000) 6737-6743
 March, J., Advanced Organic Chemistry (1977) 375-376
 Mehvar, R., J. Pharm. Pharm. Sci. 3 (1) (2000) 125-136
 20 Miyazawa, K., et al., Biochem. Biophys. Res. Comm. 163 (1989) 967-973
 Morpurgo, M., et al., Bioconj. Chem. 7 (1996) 363
 Nakamura, T., et al., Biochem. Biophys. Res. Commun. 22 (1984) 1450-1459
 Nakamura, T., et al., Nature 342 (1989) 440-443
 Okajima, A., et al., Eur. J. Biochem. 193 (1990) 375-381
 25 Parr, C., et al., Int. J. Cancer 85 (2000) 563-570
 Remington's Pharmaceutical Sciences, 18th edition, 1990, Mack Publishing Company, edited by Oslo et al. (e.g.
 pp. 1435-1712)
 Seki, T., et al., Biochem. and Biophys. Res. Comm. 172 (1990) 321-327
 Stuart, K.A., et al., International Journal of Experimental Pathology 81 (2000) 17-30
 30 Tashiro, K., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 3200-3204
 U.S. Patent No. 4,002,531
 U.S. Patent No. 4,904,584
 U.S. Patent No. 5,252,714
 U.S. Patent No. 5,382,657
 35 U.S. Patent No. 5,672,662
 U.S. Patent No. 5,977,310
 Weidner, K.M., et al., Proc. Natl. Acad. Sci. USA 88 (1991) 7001-7005
 WO 01/02017
 WO 90/04606
 40 WO 90/07938
 WO 93/23541
 WO 94/01451

SEQUENCE LISTING

5 <110> F. HOFFMANN-LA ROCHE AG
 <120> PEG-conjugates of HGF-NK4
 <130> Case 20859
 10 <140>
 <141>
 <160> 2
 15 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 1344
 20 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 25 <222> (1)..(1344)
 <400> 1
 30 caa agg aaa aga aga aat aca att cat gaa ttc aaa aaa tca gca aag 48
 Gln Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys
 1 5 10 15
 act acc cta atc aaa ata gat cca gca ctg aag ata aaa acc aaa aaa 96
 Thr Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys
 35 20 25 30
 gtg aat act gca gac caa tgt gct aat aga tgt act agg aat aaa gga 144
 Val Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly
 35 40 45
 40 ctt cca ttc act tgc aag gct ttt gtt ttt gat aaa gca aga aaa caa 192
 Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln
 50 55 60
 45 tgc ctc tgg ttc ccc ttc aat agc atg tca agt gga gtg aaa aaa gaa 240
 Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu
 65 70 75 80
 50 ttt ggc cat gaa ttt gac ctc tat gaa aac aaa gac tac att aga aac 288
 Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn
 85 90 95
 tgc atc att ggt aaa gga cgc agc tac aag gga aca gta tct atc act 336
 55 Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr
 100 105 110

EP 1 234 583 A1

	aag agt ggc atc aaa tgt cag ccc tgg agt tcc atg ata cca cac gaa	384
	Lys Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu	
	115 120 125	
5	cac agc ttt ttg cct tcg agc tat cgg ggt aaa gac cta cag gaa aac	432
	His Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn	
	130 135 140	
10	tac tgt cga aat cct cga ggg gaa gaa ggg gga ccc tgg tgt ttc aca	480
	Tyr Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr	
	145 150 155 160	
15	agc aat cca gag gta cgc tac gaa gtc tgt gac att cct cag tgt tca	528
	Ser Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser	
	165 170 175	
20	gaa gtt gaa tgc atg acc tgc aat ggg gag agt tat cga ggt ctc atg	576
	Glu Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met	
	180 185 190	
25	gat cat aca gaa tca ggc aag att tgt cag cgc tgg gat cat cag aca	624
	Asp His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr	
	195 200 205	
30	cca cac cgg cac aaa ttc ttg cct gaa aga tat ccc gac aag ggc ttt	672
	Pro His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe	
	210 215 220	
35	gat gat aat tat tgc cgc aat ccc gat ggc cag ccg agg cca tgg tgc	720
	Asp Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys	
	225 230 235 240	
40	tat act ctt gac cct cac acc cgc tgg gag tac tgt gca att aaa aca	768
	Tyr Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr	
	245 250 255	
45	tgc gct gac aat act atg aat gac act gat gtt cct ttg gaa aca act	816
	Cys Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr	
	260 265 270	
50	gaa tgc atc caa ggt caa gga gaa ggc tac agg ggc act gtc aat acc	864
	Glu Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr	
	275 280 285	
55	att tgg aat gga att cca tgt cag cgt tgg gat tct cag tat cct cac	912
	Ile Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His	
	290 295 300	
60	gag cat gac atg act cct gaa aat ttc aag tgc aag gac cta cga gaa	960
	Glu His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu	
	305 310 315 320	
65	aat tac tgc cga aat cca gat ggg tct gaa tca ccc tgg tgt ttt acc	1008
	Asn Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr	
	325 330 335	

EP 1 234 583 A1

act gat cca aac atc cga gtt ggc tac tgc tcc caa att cca aac tgt 1056
 Thr Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys
 340 345 350

5 gat atg tca cat gga caa gat tgt tat cgt ggg aat ggc aaa aat tat 1104
 Asp Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr
 355 360 365

10 atg ggc aac tta tcc caa aca aga tct gga cta aca tgt tca atg tgg 1152
 Met Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp
 370 375 380

15 gac aag aac atg gaa gac tta cat cgt cat atc ttc tgg gaa cca gat 1200
 Asp Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp
 385 390 395 400

20 gca agt aag ctg aat gag aat tac tgc cga aat cca gat gat gat gct 1248
 Ala Ser Lys Leu Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala
 405 410 415

25 cat gga ccc tgg tgc tac acg gga aat cca ctc att cct tgg gat tat 1296
 His Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr
 420 425 430

tgc cct att tct cgt tgt gaa ggt gat acc aca cct aca ata gtc taa 1344
 Cys Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val
 435 440 445

30 <210> 2
 <211> 447
 <212> PRT
 <213> Homo sapiens

35 <400> 2
 Gln Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys
 1 5 10 15
 40 Thr Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys
 20 25 30
 Val Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly
 35 40 45
 Leu Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln
 50 55 60
 45 Cys Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu
 65 70 75 80
 Phe Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn
 85 90 95

50

55

	Cys	Ile	Ile	Gly	Lys	Gly	Arg	Ser	Tyr	Lys	Gly	Thr	Val	Ser	Ile	Thr
				100					105					110		
5	Lys	Ser	Gly	Ile	Lys	Cys	Gln	Pro	Trp	Ser	Ser	Met	Ile	Pro	His	Glu
			115					120					125			
	His	Ser	Phe	Leu	Pro	Ser	Ser	Tyr	Arg	Gly	Lys	Asp	Leu	Gln	Glu	Asn
			130				135					140				
	Tyr	Cys	Arg	Asn	Pro	Arg	Gly	Glu	Glu	Gly	Gly	Pro	Trp	Cys	Phe	Thr
						150					155					160
10	Ser	Asn	Pro	Glu	Val	Arg	Tyr	Glu	Val	Cys	Asp	Ile	Pro	Gln	Cys	Ser
				165						170					175	
	Glu	Val	Glu	Cys	Met	Thr	Cys	Asn	Gly	Glu	Ser	Tyr	Arg	Gly	Leu	Met
				180					185					190		
15	Asp	His	Thr	Glu	Ser	Gly	Lys	Ile	Cys	Gln	Arg	Trp	Asp	His	Gln	Thr
			195					200					205			
	Pro	His	Arg	His	Lys	Phe	Leu	Pro	Glu	Arg	Tyr	Pro	Asp	Lys	Gly	Phe
			210				215					220				
	Asp	Asp	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Gln	Pro	Arg	Pro	Trp	Cys
			225			230					235					240
20	Tyr	Thr	Leu	Asp	Pro	His	Thr	Arg	Trp	Glu	Tyr	Cys	Ala	Ile	Lys	Thr
				245						250					255	
	Cys	Ala	Asp	Asn	Thr	Met	Asn	Asp	Thr	Asp	Val	Pro	Leu	Glu	Thr	Thr
				260					265				270			
25	Glu	Cys	Ile	Gln	Gly	Gln	Gly	Glu	Gly	Tyr	Arg	Gly	Thr	Val	Asn	Thr
			275					280					285			
	Ile	Trp	Asn	Gly	Ile	Pro	Cys	Gln	Arg	Trp	Asp	Ser	Gln	Tyr	Pro	His
			290				295					300				
	Glu	His	Asp	Met	Thr	Pro	Glu	Asn	Phe	Lys	Cys	Lys	Asp	Leu	Arg	Glu
			305			310					315					320
30	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Ser	Glu	Ser	Pro	Trp	Cys	Phe	Thr
				325						330				335		
	Thr	Asp	Pro	Asn	Ile	Arg	Val	Gly	Tyr	Cys	Ser	Gln	Ile	Pro	Asn	Cys
				340					345				350			
35	Asp	Met	Ser	His	Gly	Gln	Asp	Cys	Tyr	Arg	Gly	Asn	Gly	Lys	Asn	Tyr
			355					360					365			
	Met	Gly	Asn	Leu	Ser	Gln	Thr	Arg	Ser	Gly	Leu	Thr	Cys	Ser	Met	Trp
			370				375					380				
	Asp	Lys	Asn	Met	Glu	Asp	Leu	His	Arg	His	Ile	Phe	Trp	Glu	Pro	Asp
			385			390					395					400
40	Ala	Ser	Lys	Leu	Asn	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asp	Asp	Ala
				405						410					415	
	His	Gly	Pro	Trp	Cys	Tyr	Thr	Gly	Asn	Pro	Leu	Ile	Pro	Trp	Asp	Tyr
				420					425				430			
45	Cys	Pro	Ile	Ser	Arg	Cys	Glu	Gly	Asp	Thr	Thr	Pro	Thr	Ile	Val	
			435					440					445			

50 **Claims**

1. A conjugate comprising an N-terminal fragment of hepatocyte growth factor (HGF/SF) consisting of the hairpin domain and the four kringle regions of the α -chain and one to three polyethylene glycol group(s), said polyethylene glycol group(s) having an overall molecular weight of from about 10 to 40 kDa.
2. A conjugate according to claim 1, **characterized in that** the polyethylene glycol group(s) has/have a molecular weight of from about 20 to 40 kDa.

3. A conjugate according to claim 1 or 2, **characterized in that** said polyethylene glycol group(s) is/are (a) mono-methoxy polyethylene glycol group(s).

5 4. A conjugate according to claims 1 to 3, **characterized in that** said polyethylene glycol group(s) is/are attached to NK4 by an acyl or alkyl linkage.

5. A conjugate according to claim 1, **characterized in that** said polyethylene glycol group(s) has/have the formula




and said -CO group forms an amide bond with one of the amino groups of said N-terminal fragment of hepatocyte growth factor, wherein

X is 2 or 3;

15 m is from about 200 to about 950;

R is lower alkyl.

6. A conjugate according to claim 5 having the formula I



wherein

25 X is 2 or 3;

m is from about 200 to about 950;

n is 2 or 3;

P is said N-terminal fragment of hepatocyte growth factor without the n amino group(s) which form amide linkage(s) with the poly(ethylene glycol) group(s).

30

7. A pharmaceutical composition comprising a conjugate of claims 1 to 6 and a pharmaceutically acceptable carrier.

8. A process for preparing a pharmaceutical composition according to claim 7.

35 9. Use of a conjugate according to claims 1 to 6 for the preparation of a medicament useful in the treatment of cancer.

10. Method for the treatment of cancer diseases, comprising the steps of administering to a patient in need thereof a pharmaceutical composition according to claim 7.

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	DATE K ET AL: "HGF/NK4 IS A SPECIFIC ANTAGONIST FOR PLEIOTROPHIC ACTIONS OF HEPATOCYTE GROWTH FACTOR" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 420, no. 1, 1997, pages 1-6, XP002920323 ISSN: 0014-5793 * abstract * * figures 1-3 * * page 5, paragraph DISCUSSION - page 6 *	1-10	A61K47/48 A61P35/00
Y	DATE K ET AL: "INHIBITION OF TUMOR GROWTH AND INVASION BY A FOUR-KRINGLE ANTAGONIST (HGF/NK4) FOR HEPATOCYTE GROWTH FACTOR" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 17, no. 23, 1998, pages 3045-3054, XP001008680 ISSN: 0950-9232 * page 3049, right-hand column, last paragraph - page 3051, left-hand column, line 5 *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claim 10 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), a search has been carried out, based on the alleged effects of the compound/composition.</p>			
Place of search THE HAGUE		Date of completion of the search 16 August 2001	Examiner Dullaart, A
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published or, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 C3-82 (Pat.C37)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	KUBA K ET AL: "HGF/NK4, A FOUR-KRINGLE ANTAGONIST OF HEPATOCYTE GROWTH FACTOR, IS AN ANGIOGENESIS INHIBITOR THAT SUPPRESSES TUMOR GROWTH AND METASTASIS IN MICE" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6737-6743, XP001008887 ISSN: 0008-5472 * page 6741, paragraph DISCUSSION - page 6742 *	1-10	
Y	EP 0 816 381 A (SUMITOMO PHARMA ;NAKAMURA TOSHIKAZU (JP)) 7 January 1998 (1998-01-07) * page 9, line 3 - line 8 * * examples * * claims *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	UEMATSU Y ET AL: "Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects." JOURNAL OF PHARMACEUTICAL SCIENCES, JAN 1999, VOL. 88, NO. 1, PAGE(S) 131-135, XP002175032 * abstract * * page 133, paragraph RESULTS *	1-10	
Y	WO 94 13322 A (MARCUCCI FABRIZIO ;ERBA CARLO SPA (IT); GREGORY RUTH (IT)) 23 June 1994 (1994-06-23) * page 8 * * claims *	1-10	
	----- -/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	GAERTNER H F ET AL: "SITE-SPECIFIC ATTACHMENT OF FUNCTIONALIZED POLY(ETHYLENE GLYCOL) TO THE AMINO TERMINUS OF PROTEINS" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 7, no. 1, 1996, pages 38-44, XP000646874 ISSN: 1043-1802 * abstract * * page 39, scheme 1 * * page 42, right-hand column, paragraph 2 - page 43, left-hand column, line 3; figure 5 * * page 44, paragraph CONCLUSION *	1-10	
Y	FRANCIS G E ET AL: "PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques." INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 68, no. 1, July 1998 (1998-07), pages 1-18, XP001010042 ISSN: 0925-5710 * abstract * * page 2 * * page 6, paragraph 4.1 * * page 7 * * page 10, paragraph 4.2 - page 12, right-hand column, line 2 * * page 13, left-hand column, last line - page 15, left-hand column, line 2 * * figure 1 *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	TSUTSUMI YASUO ET AL: "PEGylation of interleukin-6 effectively increases its thrombopoietic potency." THROMBOSIS AND HAEMOSTASIS, vol. 77, no. 1, 1997, pages 168-173, XP001010032 ISSN: 0340-6245 * abstract *	1-10	
Y	TSUTSUMI YASUO ET AL: "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 15, 18 July 2000 (2000-07-18), pages 8548-8553, XP002175033 July 18, 2000 ISSN: 0027-8424 * abstract * * page 8551, left-hand column, last paragraph - right-hand column, line 5; table 3 *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	HEINZERLING LUCIE ET AL: "Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient." DERMATOLOGY (BASEL), vol. 201, no. 2, 2000, pages 154-157, XP001010033 ISSN: 1018-8665 * abstract *	1-10	
	--- -/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 10 4640

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	<p>TSUTSUMI Y ET AL: "Molecular design of hybrid tumor necrosis factor-alpha III: Polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation."</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 278, no. 3, 1996, pages 1006-1011, XP001010039</p> <p>ISSN: 0022-3565</p> <p>* abstract *</p> <p>* table 2 *</p>	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	<p>REDDY K RAJENDER: "Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs."</p> <p>ANNALS OF PHARMACOTHERAPY, vol. 34, no. 7-8, July 2000 (2000-07), pages 915-923, XP001010043</p> <p>ISSN: 1060-0280</p> <p>* abstract *</p> <p>* table 1 *</p> <p>* page 919, left-hand column, paragraph - page 921, right-hand column *</p>	1-10	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 4640

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information

16-08-2001

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0816381	A	07-01-1998	US	5977310 A	02-11-1999
			WO	9628475 A	19-09-1996
WO 9413322	A	23-06-1994	AT	168273 T	15-08-1998
			AU	678796 B	12-06-1997
			AU	5696894 A	04-07-1994
			CA	2150925 A	23-06-1994
			DE	69319740 D	20-08-1998
			DE	69319740 T	11-03-1999
			DK	675736 T	19-04-1999
			EP	0675736 A	11-10-1995
			ES	2121180 T	16-11-1998
			JP	8504202 T	07-05-1996
			US	6172202 B	09-01-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82